Literature DB >> 32057189

Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with 68 Ga: A Comparison with PSMA-11 and PSMA-617.

Lukas Greifenstein1, Nils Engelbogen1, Hanane Lahnif1, Jean-Philippe Sinnes1, Ralf Bergmann2,3, Michael Bachmann2, Frank Rösch1.   

Abstract

The L-lysine urea-L-glutamate (KuE) represents a key motif in recent diagnostic and therapeutic radiopharmaceuticals targeting the prostate specific membrane antigen (PSMA). Using a squaric acid moiety for coupling of KuE with a radioactive label, the squaric acid as a linker in the PSMA ligand seems to mimic the aromatic structure of the naphthylalanine unit on PSMA-617. In this work, we investigate the influence of squaric acid moiety on the biological activity of the compound carrying a KuE motif and three typical chelates. The derivatives TRAM.SA.KuE, DOTAGA.SA.KuE and NODAGA.SA.KuE were all synthesized in straightforward organic reactions and purified by HPLC afterward. Different amounts of tracer were labeled at different temperatures with 68 Ga. PET examinations were performed on NMRInu/nu nude mice with an LNCaP tumor on the right hind leg including ex vivo investigations of the organs. For comparison, 68 Ga-derivatives of PSMA-11 and PSMA-617, the derivatives most commonly used in clinics, were investigated in the same animal model.
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  68Ga; PET; PSMA; prostate cancer; squaric acid

Mesh:

Substances:

Year:  2020        PMID: 32057189     DOI: 10.1002/cmdc.201900559

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  5 in total

1.  Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators.

Authors:  Euy Sung Moon; Filipe Elvas; Gwendolyn Vliegen; Stef De Lombaerde; Christel Vangestel; Sven De Bruycker; An Bracke; Elisabeth Eppard; Lukas Greifenstein; Benedikt Klasen; Vasko Kramer; Steven Staelens; Ingrid De Meester; Pieter Van der Veken; Frank Rösch
Journal:  EJNMMI Radiopharm Chem       Date:  2020-07-29

2.  Multi-Modal PET and MR Imaging in the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial in Vivo Testing of Target-Specific Radioligands.

Authors:  Gordon Winter; Andrea B F Koch; Jessica Löffler; Mika Lindén; Christoph Solbach; Alireza Abaei; Hao Li; Gerhard Glatting; Ambros J Beer; Volker Rasche
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

3.  Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.

Authors:  Hanane Lahnif; Tilmann Grus; Stefanie Pektor; Lukas Greifenstein; Mathias Schreckenberger; Frank Rösch
Journal:  Molecules       Date:  2021-10-20       Impact factor: 4.411

4.  From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi.

Authors:  Lukas Greifenstein; Carsten S Kramer; Euy Sung Moon; Frank Rösch; Andre Klega; Christian Landvogt; Corinna Müller; Richard P Baum
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-14

Review 5.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.